Moderna

Open: 123.25 Close: 127.98 Change: 4.73

Stop waiting time to find out about Moderna Stock: Our AI summarizes all info about it.

This document will help you to evaluate Moderna without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Moderna are: Moderna, year, MRNA, vaccine, District, Inc, Pfizer, and the …

Concept Map

Semantic Network

Stock Summary

Moderna, Inc. discovers, develops, and commercializes messenger RNA therapeutics and vaccines. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV.

Today's Summary

Moderna (MRNA) closed at $124.94, marking a -0.53% move from the previous day. Moderna sued Pfizer and BioNTech in 2022, claiming that the companies “unlawfully copied Modernas inventions, and they have continued to use them without permission,” said chief legal officer, Moderna.

Today's News

Moderna Inc. per Employee $3.827M P/E Ratio 11.04 EPS $11.59 Yield N/A Dividend N/a Ex-Dividend date is 5.64% Average Volume 3.35M. Moderna and Pfizer are locked in a legal tussle with each other. Moderna sued Pfizer and BioNTech in 2022, claiming that the companies “unlawfully copied Modernas inventions, and they have continued to use them without permission,” said chief legal officer, Moderna. Modernas Spikevax earned $17.7 billion the same year. Moderna (MRNA) closed at $124.94, marking a -0.53% move from the previous day. Pfizer, Moderna and Novavax are already developing versions of their respective vaccines. Moderna (MRNA) has been one of the stocks most watched by Zacks users lately. Recent uptick might appease Moderna, Inc. institutional owners after losing 4.8% over the past year. The number of people with COVID-19 has been rising rapidly. Moderna has been named a top biopharmaceutical employer by Science for the past eight years. Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) reduced the risk of distant metastasis or death. New guidelines for Moderna vaccines vary depending on the vaccine that children were given in their primary series. For Moderna, immunocompromised kids between six months and five years are eligible for a booster shot. Children four and younger who were vaccinated with Moderna can only receive a Moderna booster. Prince William Health District clinics and mobile clinic unit will no longer offer doses of the Moderna monovalent primary series due to CDC and VDH inventory changes. What COVID-19 Vaccines Will Still Be Offered At The Mobile Clinic Unit? Moderna – Bivalent booster. The Prince William Health District District will close September 29, 2022. The Prince William Health District What You Should Know Bivalent COVID-19 Booster Vaccines by Pfizer-BioNTech and Moderna Available Beginning September 6. Residents of Virginia are able to schedule appointments with their healthcare providers. Moderna Inc (MRNA) stock price today, quote, latest discussions, interactive chart and news. Moderna Therapeutics (NASDAQ: MRNA) is a biotechnology company that is focused on drug discovery and drug development based on messenger RNA. Moderna Therapeutics raised a total of $1.961B in its latest funding round. Moderna is a biotechnology company that focuses on the development of messenger RNA therapeutics and vaccines. The original mRNA vaccines manufactured by Pfizer-BioNTech and Moderna contain only mRNA encoding for the spike protein of the original SARS-CoV-2.

Stock Profile

"Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts."

Keywords

The game is changing. There is a new strategy to evaluate Moderna fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Moderna are: Moderna, year, MRNA, vaccine, District, Inc, Pfizer, and the most common words in the summary are: vaccine, moderna, covid19, pfizer, stock, recommendation, offer, . One of the sentences in the summary was: Moderna (MRNA) closed at $124.94, marking a -0.53% move from the previous day. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #vaccine #moderna #covid19 #pfizer #stock #recommendation #offer.